Cancer, the leading cause of death for people under the age of 85 years in the USA, claims over 1500 lives per day [1,2]. The four most common cancers (lung, colorectal, prostate and breast cancer) account for more than half of total cancer incidences in the USA [2]. The most common cancer therapies are surgery, chemotherapy and radiation [2]. Except for a few chemotherapeutic regimens, surgery is the only definitive treatment available. Unfortunately, surgery has a 40–60% recurrence rate depending on the type of cancer [2]. This high recurrence rate has led to the combination of surgery with traditional therapies such as chemotherapy, immunotherapy and radiation. Immunotherapy utilizes the body’s own immune system to target cancer cells. Almost a century ago, it was hypothesized that a tumor can be recognized as foreign by the host and thus the immune system can be effective in eliminating these foreign cells [3]. Since then, the cancer immune response has been confirmed in knockout mice [4] and the exact phases of this mechanism, termed immunoediting, are still being rigorously studied [5]. Immunotherapy is advantageous because of its low toxicity, tumor specificity and ability to potentially produce long-term immunity. Immunotherapy seeks to eliminate cancer through both active and passive approaches [6]. Active immunotherapy utilizes our knowledge of tumor antigen expression and exploits endogenous, immunological processes of T-cell induction to eliminate the tumor [7]. Regardless of the modality, the primary goal of active immunotherapy is to prime and induce antigen-specific T-cell responses in order to eradicate residual disease and prevent postoperative recurrences. On the other hand, passive immunotherapy involves the use of immunologically active agents that are capable of exerting anti-tumor effects independently from the host’s immune system [7]. Such passive approaches include adoptive T-cell transfer techniques, which involve ex vivo amplification and reintroduction of autologous cytokine-induced killer or lymphokine-activated killer cells [7]. Various mechanisms by which immunotherapy reduces tumor burden have been elucidated, including increased intratumoral neutrophils, enhanced CD8 T-cell trafficking and decreased vasculature of the tumor [8,9].